Difference between revisions of "Bortezomib (Velcade)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
(updated content)
Line 1: Line 1:
−
Also known as PS-341.
 
−
 
 
==General information==
 
==General information==
 
Class/mechanism: Reversible inhibitor of the 26S proteasome, interfering with degradation of ubiquitinated proteins.  This disrupts normal homeostatic mechansims, leading to cell death.<ref name="insert">[http://www.millennium.com/pdf/VelcadePrescribingInformation.pdf Bortezomib (Velcade) package insert]</ref><ref>[[Media:Bortezomib.pdf | Bortezomib (Velcade) package insert (locally hosted backup)]]</ref><ref>[http://www.velcade.com Velcade manufacturer's website]</ref>  
 
Class/mechanism: Reversible inhibitor of the 26S proteasome, interfering with degradation of ubiquitinated proteins.  This disrupts normal homeostatic mechansims, leading to cell death.<ref name="insert">[http://www.millennium.com/pdf/VelcadePrescribingInformation.pdf Bortezomib (Velcade) package insert]</ref><ref>[[Media:Bortezomib.pdf | Bortezomib (Velcade) package insert (locally hosted backup)]]</ref><ref>[http://www.velcade.com Velcade manufacturer's website]</ref>  
Line 9: Line 7:
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/velcade-bortezomib-342256 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/velcade-bortezomib-342256 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 +
 +
==Diseases for which it is used==
 +
*[[Aggressive Non-Hodgkin lymphoma]]
 +
*[[Follicular lymphoma]]
 +
*[[Light-chain (AL) amyloidosis]]
 +
*[[Mantle cell lymphoma]]
 +
*[[Marginal zone lymphoma]]
 +
*[[Multiple myeloma]]
 +
*[[Transplant conditioning regimens]]
 +
*[[Waldenström macroglobulinemia]]
  
 
==Patient drug information==
 
==Patient drug information==
 
*[http://chemocare.com/chemotherapy/drug-info/bortezomib.aspx Bortezomib (Velcade) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/bortezomib.aspx Bortezomib (Velcade) patient drug information (Chemocare)]</ref>
 
*[http://chemocare.com/chemotherapy/drug-info/bortezomib.aspx Bortezomib (Velcade) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/bortezomib.aspx Bortezomib (Velcade) patient drug information (Chemocare)]</ref>
−
*Patient counseling information can be found on [http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf#page=35 page 35 of the package insert]<ref name="insert"></ref>
+
*Patient counseling information can be found in the [http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf package insert]<ref name="insert"></ref>
 
*[http://www.uptodate.com/contents/bortezomib-patient-drug-information Bortezomib (Velcade) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bortezomib-patient-drug-information Bortezomib (Velcade) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/bortezomib-patient-drug-information Bortezomib (Velcade) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bortezomib-patient-drug-information Bortezomib (Velcade) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
*5/13/2003: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021602lbl.pdf FDA approved] "for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy."
 +
*3/25/2005: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021602s006lbl.pdf FDA approved] "for the treatment of multiple myeloma patients who have received at least 1 prior therapy."
 +
*12/8/2006: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094929.htm FDA approved] "for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy."
 +
*6/23/2008: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm094633.htm FDA approved] "for the treatment of patients with multiple myeloma" (previously was only approved for patients who had received prior therapy).
 +
*10/8/2014: [http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/021602Orig1s040ltr.pdf FDA approved] for "treatment of patients with mantle cell lymphoma" (including first-line therapy for untreated patients; previously was only approved for patients who had received at least one prior treatment).
 +
 +
==Also known as==
 +
PS-341.
  
 
==References==
 
==References==

Revision as of 00:25, 10 October 2014

General information

Class/mechanism: Reversible inhibitor of the 26S proteasome, interfering with degradation of ubiquitinated proteins. This disrupts normal homeostatic mechansims, leading to cell death.[1][2][3]
Route: IV, SC
Extravasation: irritant

  • Use antiviral prophylaxis (such as with acyclovir (Zovirax) 400 mg PO daily or valacyclovir (Valtrex) 250-500 mg PO daily) to decrease risk of reactivating herpes zoster in patients treated with Bortezomib (Velcade)[4]

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 5/13/2003: FDA approved "for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy."
  • 3/25/2005: FDA approved "for the treatment of multiple myeloma patients who have received at least 1 prior therapy."
  • 12/8/2006: FDA approved "for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy."
  • 6/23/2008: FDA approved "for the treatment of patients with multiple myeloma" (previously was only approved for patients who had received prior therapy).
  • 10/8/2014: FDA approved for "treatment of patients with mantle cell lymphoma" (including first-line therapy for untreated patients; previously was only approved for patients who had received at least one prior treatment).

Also known as

PS-341.

References

  1. ↑ 1.0 1.1 1.2 Bortezomib (Velcade) package insert
  2. ↑ Bortezomib (Velcade) package insert (locally hosted backup)
  3. ↑ Velcade manufacturer's website
  4. ↑ Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009 Jan 1;115(1):229-32. link to original article PubMed
  5. ↑ Bortezomib (Velcade) patient drug information (Chemocare)
  6. ↑ Bortezomib (Velcade) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Bortezomib_(Velcade)&oldid=5120"